Swidsinski Alexander, Loening-Baucke Vera, Verstraelen Hans, Osowska Sylwia, Doerffel Yvonne
Gastroenterology, Humboldt University, Berlin, Germany.
Gastroenterology. 2008 Aug;135(2):568-79. doi: 10.1053/j.gastro.2008.04.017. Epub 2008 Apr 18.
BACKGROUND & AIMS: Dysbiosis is a key component of intestinal disorders. Our aim was to quantitatively access the biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea and evaluate the responses to Saccharomyces boulardii treatment.
We investigated punched fecal cylinders from 20 patients with chronic idiopathic diarrhea and 20 healthy controls using fluorescence in situ hybridization. Fluctuations in assembly of 11 bacterial groups were monitored weekly for 3 weeks before, during, and after oral S boulardii supplementation.
The structural organization of fecal microbiota in healthy subjects was stable and unaffected by S boulardii. The assembly of fecal microbiota in idiopathic diarrhea was markedly different, characterized by mucus depositions within feces; mucus septa and striae; marked reduction in concentrations of habitual Eubacterium rectale, Bacteroides, and Faecalibacterium prausnitzii groups; suppression of bacterial fluorescence in the center of the feces; increased concentrations and spatial shift of mucotrop bacteria to the fecal core; and increased concentrations of occasional bacteria. Except for elevated concentrations of some occasional bacterial groups, all parameters typical for diarrhea improved significantly with S boulardii treatment and most changes persisted after cessation of therapy. The improvement of the fecal microbiota was accompanied by partial (40%) and complete normalization (30%) of the diarrheal symptoms.
The fecal microbiota is highly structured. Fluorescence in situ hybridization analysis allowed us to quantitatively study the dysbiotic changes. S boulardii significantly improved the fecal biostructure in patients with diarrhea but had no influence on the feces in healthy subjects.
微生物群落失调是肠道疾病的关键组成部分。我们的目的是定量分析健康受试者和慢性特发性腹泻患者粪便微生物群的生物结构,并评估布拉酵母菌治疗的反应。
我们使用荧光原位杂交技术研究了20例慢性特发性腹泻患者和20名健康对照者的粪便圆柱体样本。在口服布拉酵母菌补充剂之前、期间和之后的3周内,每周监测11个细菌群的组装波动情况。
健康受试者粪便微生物群的结构组织稳定,不受布拉酵母菌影响。特发性腹泻患者粪便微生物群的组装明显不同,其特征为粪便内有黏液沉积;黏液隔和条纹;惯常的直肠真杆菌、拟杆菌和普拉梭菌浓度显著降低;粪便中心细菌荧光受到抑制;嗜黏液细菌浓度增加并向粪便核心空间转移;偶见细菌浓度增加。除了一些偶见细菌群浓度升高外,腹泻的所有典型参数在布拉酵母菌治疗后均有显著改善,且大多数变化在治疗停止后持续存在。粪便微生物群的改善伴随着腹泻症状部分(40%)和完全(30%)正常化。
粪便微生物群具有高度的结构。荧光原位杂交分析使我们能够定量研究失调变化。布拉酵母菌显著改善了腹泻患者的粪便生物结构,但对健康受试者的粪便没有影响。